COMBINED AMENDMENT & PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity)

Docket No. **ARC 2630**



•		P. F.	TRADEMARK BE			Hyl a
	The	fee for the amendment and	extension of time is t	o be paid as follo	ws:	571008
		A check in the amount of	\$380.00 for	the amendment a	and extension of time	e is enclosed.
	×	Please charge Deposit Acc A duplicate copy of this she		in the amo	ount of \$380.00	, ~ , .
	×	 The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. A duplicate copy of this sheet is enclosed. Any additional filing fees required under 37 C.F.R. 1.16. Any patent application processing fees under 37 CFR 1.17. 				
	⊠	If an additional extension of which may be required to D				nd charge any additional fee this sheet is enclosed.
04/07 01 F0)1999 T!	SUGGS 00000004 011173 0898	7372			
VI F	1110	360200 011				
		Owen Bate Signature	ا	Dated: M	arch 19, 1999	_
	Owen .	J. Bates, Reg. No. 40,346		ſſ	I His Abst Abst 4	and the late of th
		Corporation		- 11	I certify that this docu	ument and fee is being deposited with the U.S. Postal Service as
		ge Mill Road			first class mail under 37	C.F.R. 1.8 and is addressed to the
	i raio A	lto, CA 94303-0802		l):	Assistant Commissione	r for Patents, Washington, D.C.

(650) 496-8267

20231.

Dueng Bates
Signature of Person Mailing Correspondence

Owen J. Bates Henrietta Votaw

Typed or Printed Name of Person Mailing Correspondence

CC:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 1999.

ALZA Corporation

By Owen J. Bates

Owen J. Bates

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: VENKATRAMAN, et al

Attorney Docket No.: ARC-2630

Serial No.:

08/987,372

Group Art Unit: 1615

Filed:

09 December 1997

Examiner:

WEBMAN, E.

Title:

Pharmaceutical Hydrogel Formulations,

and Associated Drug Devices and

Methods

AMENDMENT and RESPONSE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The present AMENDMENT and REMARKS are made in reply to the Office Action mailed 19 October 1998. This is the first office action following the filing of the application on 09 December 1997.

AMENDMENT

IN THE CLAIMS:

Please cancel claims 1-21, 23, 26-28, and 31-38 without prejudice or disclaimer.

ARC-2630 Office Action Response 08/987,372

A